Journal article icon

Journal article

Non-Crosslinked Hyaluronic Acid Redensity 1<sup>®</sup> Supports Cell Viability, Proliferation, and Collagen Deposition in Early Burn Management

Abstract:
Background/Objectives: Burn injuries pose a significant challenge due to tissue damage and impaired healing. Cell-based therapies offer promise by delivering therapeutic cells to the wound site. However, effective cell delivery remains a critical hurdle. This study investigates the potential of non-crosslinked hyaluronic acid (HA) as a simple, versatile carrier for delivering autologous keratinocytes and fibroblasts to treat early burn wounds. Methods: Primary keratinocytes and fibroblasts were isolated from uninjured adult skin. In addition, fibroblasts and adipose stem cells (ASC) from polydactyly and progenitor fibroblasts were used. Non-cross-linked HA Redensity 1® (RD1) solutions of varying concentrations were prepared and applied to various in vitro models. Cell viability, proliferation, migration, and collagen stimulation were assessed using standard assays. Additionally, cells were suspended in Redensity 1 and applied to an in vitro de-epidemalized dermis (DED) wound model to examine cell delivery and tissue reformation. Results: Preliminary data demonstrated the feasibility of using non-cross-linked HA RD1 gel as a cell carrier. RD1 gel enhanced cell viability, retention, migration, and collagen deposition. Histological analysis revealed improved cell adhesion and migration. Conclusions: This study provides valuable insight into the potential of non-cross-linked HA RD1 as a simple and effective delivery vehicle for cell therapies in early burn care. Successful translation of this approach could significantly improve clinical outcomes for burn patients.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.3390/pharmaceutics18010021

Authors

More by this author
Role:
Author
ORCID:
0009-0002-7226-485X
More by this author
Role:
Author
ORCID:
0009-0002-0037-8276
More by this author
Role:
Author
ORCID:
0000-0003-4695-1816
More by this author
Institution:
University of Oxford
Role:
Author


Publisher:
MDPI
Journal:
Pharmaceutics More from this journal
Volume:
18
Issue:
1
Pages:
21
Publication date:
2025-12-23
Acceptance date:
2025-12-19
DOI:
EISSN:
1999-4923
ISSN:
1999-4923
Pmid:
41599128


Language:
English
Keywords:
Pubs id:
2366318
UUID:
uuid_b504a03e-74e3-4e2b-9a76-b69eb042c198
Local pid:
pubs:2366318
Source identifiers:
3727857
Deposit date:
2026-02-05
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP